All In Biotech

Drug Trial Radar · NCT07743164

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

A Phase 3, Open-Label, Multicenter, Randomized Study of Raludotatug Deruxtecan (MK-5909, R-DXd) With or Without Bevacizumab Versus Standard-of-Care Platinum-Based Doublet Chemotherapy With or Without Bevacizumab in Participants With Advanced Platinum-Sensitive High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Progressed During First-Line PARPi Maintenance (ENGOT-ov107 / GOG-3142 / REJOICE-Ovarian05)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 646 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

646

Planned (sponsor's estimate)

Start

Oct 7, 2026

Primary completion

Aug 31, 2031

Study completion Aug 31, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Aug 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat advanced, high-grade ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body (metastatic) and may not be removed with surgery. High-grade means the cancer cells grow and spread quickly. This trial includes types of OC that started in cells that cover the ovaries, in the lining of the belly, or in the fallopian tubes. The usual treatment for high-grade OC may include one or both of these: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing. * Bevacizumab, which is a targeted therapy that works to control how specific types of cancer cells grow and spread and targets tumor blood vessels. Researchers want to learn about the trial medicine, raludotatug deruxtecan (also called R-DXd or MK-5909), when given with and without bevacizumab and how participants respond to it. R-DXd is an antibody drug conjugate (ADC). An ADC is a type of medicine that attaches to a specific target on cancer cells and delivers treatment to destroy those cells. The goals of this trial are to learn if participants who receive R-DXd, with or without bevacizumab, live longer overall and without their cancer growing or spreading compared to those who receive usual treatment.

Conditions

  • Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer

Interventions

  • R-DXdBiological

    R-DXd alone or in combination with bevacizumab administered via IV infusion

  • BevacizumabDrug

    Bevacizumab 10 or 15 mg/kg administered via IV infusion on day 1 q3w

  • CarboplatinDrug

    Carboplatin area under the curve (AUC) 5 mg/mL\*min or AUC 4 mg/mL\*min administered on day 1 q3w for a maximum of 8 cycles

  • PaclitaxelDrug

    Paclitaxel 175 mg/m\^2 administered via IV infusion on day 1 q3w for a maximum of 8 cycles

  • GemcitabineDrug

    Gemcitabine 1000 mg/mL administered via IV infusion on day 1 and day 8 of each 3-week cycle for a maximum of 8 cycles

  • Pegylated liposomal doxorubicin (PLD)Drug

    PLD 30 mg/m\^2 administered via IV infusion on day 1 of each 4-week cycles for a maximum of 8 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Up to approximately 3 years
  2. Overall Survival (OS)Time frame: Up to approximately 4 years

Locations

9 sites in 5 countries. Site status is shown where the registry gives one.

  • MemorialCare Orange Coast Medical Center ( Site 0032)

    Fountain Valley, California · Recruiting

  • Orlando Health Cancer Institute ( Site 0018)

    Orlando, Florida · Recruiting

  • Lahey Clinic ( Site 0042)

    Burlington, Massachusetts · Recruiting

  • JPS Oncology and Infusion Center ( Site 0019)

    Fort Worth, Texas · Recruiting

  • Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology ( Site 9000)

    Wuhan, Hubei, China · Recruiting

  • Hadassah Medical Center ( Site 2700)

    Jerusalem, Israel · Recruiting

  • Sourasky Medical Center ( Site 2701)

    Tel Aviv, Israel · Recruiting

  • Seoul National University Hospital ( Site 5202)

    Seoul, South Korea · Recruiting

  • National Cheng Kung University Hospital ( Site 5304)

    Tainan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.